Detailed Answer
Erectile dysfunction (ED) treatments vary significantly in their onset of action, with some providing results within minutes while others may take longer but offer different benefits. According to the 2025 EAU Guidelines, phosphodiesterase type 5 inhibitors (PDE5Is) remain the first-line therapy for most men with ED, with varying onset times depending on the specific medication.¹
Among oral medications, avanafil stands out as the fastest-acting PDE5I, with effectiveness beginning 15-30 minutes after intake. Clinical studies show successful sexual attempts in 47-59% of men taking avanafil compared to 28% with placebo.² Sildenafil and vardenafil typically become effective within 30-60 minutes, with one study showing vardenafil enabling satisfactory erections within 15 minutes in approximately one-third of men.³ Tadalafil has a slower onset of 30 minutes to 2 hours but offers the longest duration of action—up to 36 hours—making it suitable for men preferring spontaneous rather than scheduled sexual activity.⁴
For men who require even faster results or don’t respond to oral medications, intracavernosal injection therapy with alprostadil provides erections within 5-15 minutes. The EAU Guidelines recognize this as an alternative first-line therapy for well-informed patients or as a second-line option with efficacy rates of 70-85%.⁵ However, these injections have relatively high discontinuation rates due to pain, prolonged erections, or the invasive nature of the treatment.
Penile implants represent the fastest on-demand solution for ED, providing immediate erection capability whenever desired. The 2025 EAU Guidelines recommend implants for patients who fail other treatments or prefer a definitive solution.⁶ Two main types are available: inflatable devices (two- and three-piece) and semi-rigid implants. The three-piece inflatable prostheses are often preferred for providing the most natural erections, while semi-rigid devices offer simpler operation but remain permanently firm.⁷ Patient satisfaction rates with penile implants are exceptionally high (92-100% for patients and 91-95% for partners), making them an excellent option for appropriate candidates despite their surgical nature.⁸
When considering treatment speed, it’s important to note that the EAU Guidelines emphasize personalized treatment approaches based on invasiveness, efficacy, safety, cost, and patient preference.⁹ For instance, while vacuum erection devices provide relatively quick results (5-10 minutes), they are mechanical rather than pharmacological and may be less convenient than other options. Similarly, low-intensity shockwave therapy may improve response to faster-acting treatments but doesn’t itself provide immediate results.
For men with ED following radical prostatectomy, the guidelines note that early intervention with any ED treatment affects natural recovery time.¹⁰ In this population, combination therapy with vacuum devices and PDE5Is offers advantages over monotherapy, potentially providing faster and more reliable results than either treatment alone.¹¹
The EAU Guidelines stress the importance of patient education about proper medication use, as incorrect administration is a common cause of perceived treatment failure.¹² For optimal results with any ED treatment—particularly the faster-acting options—patients should receive thorough counseling on correct usage, realistic expectations, and potential side effects.
From the Guidelines
Phosphodiesterase type 5 inhibitors (PDE5Is) remain the first-line therapy for most men with ED. Among oral medications, avanafil stands out as the fastest-acting PDE5I, with effectiveness beginning 15-30 minutes after intake. Intracavernosal injection therapy with alprostadil provides erections within 5-15 minutes. Penile implants represent the fastest on-demand solution for ED, providing immediate erection capability whenever desired.